Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;16(4):365-371.
doi: 10.1080/17460441.2021.1854221. Epub 2020 Dec 28.

Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges

Koippallil Gopalakrishnan Aghila Rani  1 , Mohamad A Hamad  2 , Dana M Zaher  3 , Scott McN Sieburth  4 , Navid Madani  5 , Taleb H Al-Tel  6
Affiliations

Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges

Koippallil Gopalakrishnan Aghila Rani et al. Expert Opin Drug Discov. 2021 Apr.

Abstract

Introduction: Despite advances in drug research and development, our knowledge of the underlying molecular mechanisms of many diseases remains inadequate. This have led to limited effective medicines for several diseases. To address these challenges, efficient strategies, novel technologies, and policies are urgently needed. The main obstacles in drug discovery and development are the mounting cost, risk, and time frame needed to develop new medicines. Fair pricing and accessibility is another unmet global challenge.Areas covered: Here, the authors cover the pace, risks, cost, and challenges facing drug development processes. Additionally, they introduce disease-associated data which demand global attention and propose solutions to overcome these challenges.Expert opinion: The massive challenges encountered during drug development urgently call for a serious global rethinking of the way this process is done. A partial solution might be if many consortiums of multi-nations, academic institutions, clinicians, pharma companies, and funding agencies gather at different fronts to crowdsource resources, share knowledge and risks. Such an ecosystem can rapidly generate first-in-class molecules that are safe, effective, and affordable. We think that this article represents a wake-up call for the scientific community to immediately reassess the current drug discovery and development procedures.

Keywords: Alzheimer’s disease; COVID-19; cancer; clinical trials; drug development; drug failure; effective drugs; infectious diseases; malaria; rare diseases.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Comparison between the traditional vaccine development timeline and the accelerated development time line in response to the COVID-19 pandemic
Figure 2.
Figure 2.
Schematic representation depicting the challenges facing the current drug development process and proposed solutions toward rapid delivery of novel, affordable and effective therapeutics
See this image and copyright information in PMC

References

    1. Lambert H, Gupte J, Fletcher H, et al. COVID-19 as a global challenge: towards an inclusive and sustainable future. Lancet Planet Health. 2020;4(8):e312–e314. - PubMed
    1. McKee M, Stuckler D.. If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future. Nat Med. 2020;26(5):640–642. - PubMed
    1. Thorlund K, Dron L, Park J, et al. A real-time dashboard of clinical trials for COVID-19. Lancet Digital Health. 2020;2(6):e286–e287. - PMC - PubMed
    1. Callaway E. What Pfizer’s landmark COVID vaccine results mean for the pandemic. Nature. 2020. Epub ahead of print. DOI: 10.1038/d41586-020-03166-8 - DOI - PubMed
    1. Ashley EA, Pyae Phyo A, Woodrow CJ. Malaria. Lancet. 2018;391(10130):1608–1621. - PubMed

Publication types